Everybody is talking about the Shroom Boom

The psychedelics boom continues in the United States, and every week brings a new development to the burgeoning sector. Psychedelic medicine has shown great promise, so much so that the U.S. FDA and Health Canada have started speeding up psychedelic substances like psilocybin, MDMA, and ketamine for research and development. Suddenly, with the federal government supporting rather than hindering medical research, the psychedelics industry really took off. Psilocybin, the active ingredient in magic mushrooms, has stolen the limelight in the past few months thanks to several positive legislative developments. Back in 2019, Denver and Oakland took an important first step to bring this wonder drug to the masses after decriminalizing psilocybin. Since then, the psilocybin dynamic has only accelerated around the world. What is driving the recent mushroom boom amid the global pandemic? The same factors that drove the cannabis boom a few years ago: changed laws, changed science, and changed consumer attitudes. With that in mind, here are some of the best psychedelic / psilocybin stocks to buy for potentially huge profits. #1. Mind medicine Mind Medicine (MindMed) Inc. (OTCMKTS: MMEDF) has established itself as a leader in the emerging psychedelic / psilocybin drug space. MindMed is a midsize company with a market capitalization of $ 420 million - but with potentially huge upside potential over the next few years. MindMed is up a staggering 610% since the start of the year and 735% in the last 12 months. MindMed has a pretty simple business idea. The company has worked hard to build a compelling portfolio of psychedelic-inspired drugs. If these drugs are successful, they could spark massive growth for MindMed. \# 2. Champignon Brands Champignon Brands Inc. (CSE: SHRMF) does pretty much the same thing as MindMed, but with a bigger focus on treating even bigger problems: depression and PTSD. Champignon Brands is pursuing the use of dissociative psychedelics such as ketamine, psilocybin and MDMA to treat depression and PTSD with its promising drugs in preclinical studies. The only reason this inventory hasn't soared like MindMed is because it can take longer for a high-yielding product to hit the market. \# 3. Revive Therapeutics While MindMed and Champignon Brands are pure toy mushroom stocks, Revive Therapeutics (OTC: RVVTF) is more of a mixed game in this megatrend. In fact, Revive is more of a marijuana company focused on developing CBD pharmaceuticals that can be used to treat rare areas of inflammation such as liver disease. Revive's drugs have already received FDA approval for orphan drug status for the treatment of CBD and liver disease.